[Correction added on 9 April 2014 after first online publication: article was made Open Access and copyright line was amended.]
Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine
Article first published online: 15 MAR 2014
© The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of EAN.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
European Journal of Neurology
Volume 21, Issue 6, pages 851–859, June 2014
How to Cite
Diener, H.-C., Dodick, D. W., Turkel, C. C., Demos, G., DeGryse, R. E., Earl, N. L. and Brin, M. F. (2014), Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. European Journal of Neurology, 21: 851–859. doi: 10.1111/ene.12393
- Issue published online: 8 MAY 2014
- Article first published online: 15 MAR 2014
- Manuscript Accepted: 28 JAN 2014
- Manuscript Received: 15 OCT 2013
- Allergan Inc.
- Imprint Publication Science, New York, NY
|ene12393-sup-0001-FigS1.docx||Word document||68K||Figure S1. Adverse events reported in ≥2% of patients clustered by system organ class.|
Table S1. Summary of studies.
Table S2. Treatment-related adverse events reported in ≥2% of patients.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.